飛揚集團(01901.HK)建議終止現有購股權計劃及採納新購股權計劃
格隆匯6月13日丨飛揚集團(01901.HK)公告,於2025年6月13日,董事會已議決建議採納新購股權計劃及終止現有購股權計劃,以供股東於股東特別大會上批準。
現有購股權計劃採納日期爲2019年6月11日。根據其條款,現有購股權計劃須爲有效及具效力直至2029年6月10日,即現有購股權計劃採納日期後10年。建議於採納新購股權計劃後,現有購股權計劃將會終止。
聯交所就上市發行人購股權計劃及股份獎勵計劃對上市規則所作修訂於2023年1月1日生效。就此而言,董事會建議終止現有購股權計劃並採納新購股權計劃,其將自採納新購股權計劃日期起計10年內有效。新購股權計劃的條文將符合股份計劃修訂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.